ClinicalTrials.gg
CompletedNCT06379061Updated Jun 5, 2025

Access MeMed BV Assay Clinical Study Collection Protocol - Infectious Adult and Pediatric Cohorts

An observational study in Infection, Bacterial and Infection Viral, sponsored by Beckman Coulter, Inc.. Completed at 4 sites in United States. Open to participants aged 90 Days to 89 Years. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Beckman Coulter, Inc. (part of Danaher Corporation) · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
650
Ages
90 Days to 89 Years
Sex
All
01

Study summary

The purpose of the pivotal study is to collect blood specimens and clinical data from pediatric (>90 days old) and adult (≥18 years old) patients presenting with signs and symptoms suggestive of acute bacterial or viral infection. These samples will be used to establish the diagnostic performance of MeMed BV™ for differentiating bacterial from viral infection using method comparison and/or method concordance.

Read the detailed description

The objective of this study is to collect blood specimens from pediatric (>90 days old) and adult patients (≥18 years old) presenting with signs and symptoms suggestive of acute bacterial or viral infection from hospital, Emergency Department, or Urgent Care Centers for comparative testing on the Access 2 and DxI 9000 Immunoassay Analyzers.

02

Conditions studied

  • Infection, Bacterial
  • Infection Viral
03

In context

Bacterial Infections

584 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

This study's enrollment of 650 is above the median of 200 across 185 observational studies indexed under Bacterial Infections.

Browse Bacterial Infections studies →

Lead sponsor

Beckman Coulter, Inc. is the lead sponsor of 31 studies on the registry; 1 is open to participants now.

First submitted after Beckman Coulter, Inc. became part of Danaher Corporation.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
90 Days to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric and adult patients presenting to the Emergency Department or Urgent Care Center with signs and symptoms suggestive of acute bacterial or viral infection.

The study sample size will be divided into the following:

  • Pediatric (>90 days - \<18 yrs. of age) population sample target of 30 enrolled subjects.
  • Adult (≥18 yrs. of age) population sample target of 214 adult patients enrolled subjects.

The target population will be representative of US demographics. This sample size aligns with comparator device studies. Pediatric sample collection will be separated into the following three (3) age categories:

  • Age over 90 days to \<2 yrs.
  • Age 2 yrs. to \<12 yrs.
  • Age 12 yrs. to \<18 yrs.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 90 days of age.
  • Clinical suspicion of acute bacterial or viral infection.
  • Temperature ≥ 37.8°C (100°F) (any body site, any measurement device, including self-reported) or tactile fever, either of them noted at least once within the last 7 days.
  • Current disease duration ≤ 7 days.

Exclusion criteria

Exclusion Criteria:

  • Previously enrolled
  • Insufficient sample volumes obtained

    • For the adult and pediatric populations, \< 1.2 mL serum volume
  • Sample handling errors
  • Another unrelated episode of febrile infection within the past 2 weeks
  • Suspicion and/or confirmed diagnosis of infectious gastroenteritis/ colitis.
  • ≥48 hours of oral antibiotic treatment
  • ≥12 hours of intravenous\intramuscular antibiotic treatment
  • Human Immunodeficiency Viruses (), Virus (HBV), or Virus (HCV) infection (self-declared or known from medical records)
  • A proven or suspected infection on presentation with Mycobacterial (e.g., Tuberculosis, MAC), parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen
  • Active inflammatory disease (e.g., Inflammatory Bowel Disease [IBD], Systemic Lupus Erythematosus [SLE], Juvenile Idiopathic Arthritis [JIA], Rheumatoid Arthritis [RA], Kawasaki, other vasculitis)
  • Major trauma and\or burns in the last 7 days.
  • Major surgery in the last 7 days
  • Congenital immune deficiency (CID)
  • Acquired immune deficiency\modulation state including

    1. Active treated within last 6 months
    2. Current treatment with immune-suppressive or immune-modulating therapies, including without limitations:

    i. Administration of P.O.\IV\IM high dose >1mg/kg/day prednisone (or equivalent) at some point in the past 10 days or daily continuous use of steroids > 0.25 mg/kg/day in the past 7 days ii. Monoclonal antibodies, anti-TNF agents iii. Intravenous immunoglobulin (IVIG) iv. Cyclosporine, Cyclophosphamide, Tacrolimus, Azathioprine, Methotrexate v. G/GM-CSF Interferons c. Post solid organ/bone marrow transplant patients d. Asplenia, sickle cell disease

  • Indwelling central venous catheter
  • Cystic Fibrosis
  • Pregnancy - self-reported or medically known
  • Other severe illnesses that affect and quality of life such as:

    1. Severe psychomotor retardation
    2. Congenital metabolic disorder
    3. End stage renal disease, advanced heart failure ( 3/4), advanced (GOLD 3/4)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
650 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Adult and Pediatrics

    A minimum of 244 serum samples will be collected at a minimum of two (2) US locations from enrolled pediatric and adult patients presenting signs and symptoms suggestive of acute bacterial or viral infection. The number of patients enrolled is based on total volume required to run analytical comparison studies under a future testing protocol.

    Other: Adult and Pediatrics

Interventions

  • OtherAdult and Pediatrics

    This is an observational study. This protocol is for blood draw enrollment. These samples will be collected and binned by their results from the MeMed BV assay. Samples collected will be used for an analytical comparison study under a future testing protocol. These samples will be used to establish the diagnostic performance of MeMed BV test on BEC Access Immunoassay Systems for differentiating bacterial from viral infection.

06

What researchers measure

Primary outcomes

  1. Blood Specimen Collection

    Collect blood specimens across multiple age ranges presenting symptoms of acute or viral infection

    Time frame: Less or equal to seven days

07

Study locations

4 sites
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Massachusetts General Brigham
    Boston, Massachusetts 02114, United States
  • Wayne State University
    Detroit, Michigan 48202, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jan 2025, 7 months.

Of 80 observational studies under Bacterial Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2024
First posted
Apr 23, 2024
StartActual
Jun 12, 2024
Primary completionActual
Jan 31, 2025
CompletionActual
Apr 30, 2025
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06379061
Collaborators
MeMed Diagnostics Ltd.
Responsible party
Sponsor
First posted
Apr 23, 2024
Start date
Jun 12, 2024
Primary completion
Jan 31, 2025
Completion
Apr 30, 2025
Last update
Jun 5, 2025

Study contacts

David Haan
study director · Beckman Coulter, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion